Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Mavrilimumab · KPL-301, CAM-3001

Monoclonal antibody · Antagonist of granulocyte-macrophage colony-stimulating factor receptor alpha (CSF2RA) · developed by MedImmune LLC

Phase 2/3 Most advanced trial (none active)
1 Registered trials

What is Mavrilimumab?

Mavrilimumab is a human IgG4 monoclonal antibody that binds the alpha chain of the granulocyte-macrophage colony-stimulating factor receptor (GM-CSF-Rα), inhibiting GM-CSF-mediated signaling in granulocytes and monocytes. It is being studied in COVID-19 and pneumonia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KPL-301, CAM-3001
Drug type
Monoclonal antibody
Targets
granulocyte-macrophage colony-stimulating factor receptor alpha (CSF2RA)
Mechanism
Antagonist of granulocyte-macrophage colony-stimulating factor receptor alpha (CSF2RA)
Pathways
GM-CSF signaling pathway
Therapy area
Infectious disease, Respiratory
Developer
MedImmune LLC
In trials of
KNSA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
1158JD1P9A

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04447469 Phase 2/3 COVID Completed KNSA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.